Gastrointestinal Cancers Symposium (ASCO GI) | Conference

Ramucirumab Beneficial in Advanced Gastric/GEJ Cancers Regardless of Age

January 21st 2017

Patients in all age groups derived a survival benefit from treatment of advanced gastric or gastroesophageal juncture cancer with the monoclonal antibody ramucirumab, an analysis of 2 randomized trials showed.

Progression Type in HCC Influences Survival Duration

January 21st 2017

Patients with advanced hepatocellular carcinoma had a worse survival following progression if they developed new extrahepatic lesions as opposed to other types of progression, supporting the concept of post-progression survival and the influence of different patterns of progression, according to an analysis of the phase III RESORCE trial.

Dr. Chau on Ramucirumab Plus Pembrolizumab for Gastric/GEJ Cancer

January 21st 2017

Ian Chau, MD, consultant medical oncologist, Royal Marsden Hospital, discusses interim safety and clinical activity results in patients with advanced gastric or gastroesophageal junction adenocarcinoma from a multi-cohort phase I study of ramucirumab plus pembrolizumab.

Dr. Finn on the Promise of Regorafenib for the Treatment of HCC

January 21st 2017

Richard Finn, MD, associate professor of medicine at the UCLA David Geffen School of Medicine, discusses the promise of regorafenib (Stivarga) for the treatment of hepatocellular carcinoma (HCC), as seen in the phase III RESORCE trial.

Trastuzumab Beyond Progression Shows Promise in HER2+ Gastric Cancers

January 21st 2017

Results from a retrospective multicenter study suggest that continuing trastuzumab beyond progression may improve survival in patients with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma who progress on first-line trastuzumab plus platinum-based chemotherapy.

Surgical Palliation Enables Solid Food Intake in Advanced Incurable Gastric Cancer

January 21st 2017

Surgical palliation in patients treated for malignant gastric outlet obstruction maintains quality of life and improves solid food intake for at least 3 months after surgery.

Pembrolizumab/Ramucirumab Combo Active in Gastric Cancers

January 20th 2017

A combination regimen of pembrolizumab plus ramucirumab demonstrated modest activity in patients with previously treated gastric or gastroesophageal juncture cancer.

Nivolumab Improves Survival in Advanced Gastric/GEJ Cancer

January 20th 2017

Treatment with nivolumab reduced the risk of death by 37% compared with placebo for patients with advanced gastric or gastroesophageal junction cancer following second or later-line chemotherapy.

Dr. Overman Discusses Updated Findings of CheckMate-142 in Patients With MSI-H mCRC

January 20th 2017

Michael J. Overman, MD, medical oncologist, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses updated results from the CheckMate 142 trial, which investigated nivolumab (Opdivo) alone or in combination with ipilimumab (Yervoy) in patients with DNA mismatch repair deficient/microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC).

Dr. Strosberg on Quality of Life Findings for Lu-Dotatate in Patients with Midgut NETs

January 20th 2017

Jonathan R. Strosberg, MD, associate professor, Moffitt Cancer Center, discusses quality of life findings in patients with midgut neuroendocrine tumors.

PET-Guided Treatment Improves Outcomes in Esophageal Cancer

January 18th 2017

Switching neoadjuvant chemotherapy regimens based on PET imaging after induction chemotherapy improved pathologic complete response rates in patients with esophageal and gastroesophageal junction cancers.

Watch-and-Wait Approach a Potential Option for Patients With Rectal Cancer

January 18th 2017

A watch-and-wait approach is emerging as a potential treatment strategy for patients with rectal cancer.

Analysis Shows Link Between Daily Physical Activity and Improved mCRC Outcomes

January 18th 2017

Patients with metastatic colorectal cancer who engaged in daily moderate physical activity demonstrated a reduction in mortality and cancer progression.

Dr. Bekaii-Saab on Benefits Associated With Regorafenib for CRC

February 29th 2016

Tanios Bekaii-Saab, MD, associate professor, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, discusses the benefits patients receive with regorafenib for the treatment of colorectal cancer.

Mismatch Repair-Deficient GI Tumors Respond to Anti—PD-1 Therapy

January 26th 2016

Mismatch repair-deficient gastrointestinal tumors are highly responsive to checkpoint blockade with anti-PD-1 therapy.

PFS in Metastatic Colorectal Cancer Similar with Two Chemo Backbones

January 26th 2016

A potential biomarker to guide chemotherapy for metastatic colorectal cancer failed to stratify patients by progression-free survival or responsiveness to bevacizumab.

Dr. Kunz on the CLARINET Study for GEP-NETs

January 26th 2016

Pamela L. Kunz, MD, assistant professor, Division of Oncology, Stanford University School of Medicine, discusses tumor response in the CLARINET study, which examined lanreotide depot versus placebo in patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

Dr. Melis on Avoiding Surgery for Patients With Rectal Cancer

January 26th 2016

Marcovalerio Melis, MD, associate professor, Department of Surgery, NYU Langone Medical Center, discusses a study examining if surgery can be avoided in patients with advanced rectal cancer by using diffusion-weighted magnetic resonance imaging to predict pathologic response.

Three Drugs Marginally Better Than Two in First-Line Metastatic Colorectal Cancer

January 25th 2016

Patients with metastatic colorectal cancer (mCRC) had marginal yet inconsistent improvement in clinical outcomes when treated with a three-drug chemotherapy regimen plus bevacizumab compared with a doublet-bevacizumab regimen.

Neoadjuvant Carboplatin/Paclitaxel Showing Potential in Esophageal Cancer

January 25th 2016

Neoadjuvant treatment with carboplatin and paclitaxel-based chemotherapy produced a 27.9% pathologic complete response rate in patients with resectable esophageal cancer, according to results of the NEOSCOPE trial.